Marta Castiglia

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5410633/marta-castiglia-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32	772	17	27
papers	citations	h-index	g-index
33	911	4.2 avg, IF	3.65
ext. papers	ext. citations		L-index

#	Paper	IF	Citations
32	TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. <i>Journal of Clinical Pathology</i> , 2021 ,	3.9	4
31	Targeted Therapy. UNIPA Springer Series, 2021, 181-206	0.1	
30	Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma. <i>Journal of Molecular Pathology</i> , 2021 , 2, 173-196	0.4	10
29	Cell quality evaluation with gene expression analysis of spheroids (3D) and adherent (2D) adipose stem cells. <i>Gene</i> , 2021 , 768, 145269	3.8	4
28	Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses.	5.4	4
27	Not all 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211049779	5.4	0
26	Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in Genes. <i>Cancers</i> , 2020 , 12,	6.6	14
25	Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. <i>Cancers</i> , 2020 , 12,	6.6	8
24	Cell-free DNA and exoDNA analysis in metastatic colorectal cancer patients (mCRC) <i>Journal of Clinical Oncology</i> , 2020 , 38, e16093-e16093	2.2	O
23	Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920942378	5.4	22
22	Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919874653	5.4	18
21	An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 485-496	4.1	6
20	Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919839928	5.4	29
19	Adipose tissue, angiogenesis and angio-MIR under physiological and pathological conditions. <i>European Journal of Cell Biology</i> , 2019 , 98, 53-64	6.1	7
18	Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis. <i>Current Cancer Drug Targets</i> , 2018 , 18, 697-705	2.8	23
17	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2018 , 8, 13379	4.9	48
16	Spheroids from adipose-derived stem cells exhibit an miRNA profile of highly undifferentiated cells. <i>Journal of Cellular Physiology</i> , 2018 , 233, 8778-8789	7	14

LIST OF PUBLICATIONS

15	EGFR inhibition in NSCLC: New findings[land opened questions?. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 112, 126-135	7	20
14	Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 937, 207-28	3.6	43
13	Exosomal miRNA Analysis in Non-small Cell Lung Cancer (NSCLC) PatientsVPlasma Through qPCR: A Feasible Liquid Biopsy Tool. <i>Journal of Visualized Experiments</i> , 2016 ,	1.6	38
12	Nintedanib in NSCLC: evidence to date and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 188-97	5.4	17
11	A headlight on liquid biopsies: a challenging tool for breast cancer management. <i>Tumor Biology</i> , 2016 , 37, 4263-73	2.9	17
10	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. <i>Oncotarget</i> , 2016 , 7, 60712-60722	3.3	79
9	Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?. <i>Oncotarget</i> , 2016 , 7, 29321-32	3.3	21
8	KRAS and BRAF as prognostic biomarkers in patients undergoing surgical resection of colorectal cancer liver metastasis: A systematic review and meta-analysis <i>Journal of Clinical Oncology</i> , 2016 , 34, 3565-3565	2.2	
7	Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. <i>Oncotarget</i> , 2016 , 7, 47821-47830	3.3	28
6	Dietary restriction: could it be considered as speed bump on tumor progression road?. <i>Tumor Biology</i> , 2016 , 37, 7109-18	2.9	21
5	Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?. <i>Analytical Cellular Pathology</i> , 2015 , 2015, 690916	3.4	61
4	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 89, 300-13	7	56
3	Liquid biopsies in lung cancer: the new ambrosia of researchers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014 , 1846, 539-46	11.2	95
2	ALK and crizotinib: after the honeymoon what else? Resistance mechanisms and new therapies to overcome it. <i>Translational Lung Cancer Research</i> , 2014 , 3, 250-61	4.4	37
1	Hypoxia and human genome stability: downregulation of BRCA2 expression in breast cancer cell lines. <i>BioMed Research International</i> , 2013 , 2013, 746858	3	24